Provectus Pharmaceuticals Inc. (OTCB: PVCT), Knoxville, Tenn.
Product: PH-10
Business: Autoimmune
Molecular target: NA
Description: Topical aqueous hydrogel formulation of Rose Bengal disodium
Indication: Treat mild to moderate plaque psoriasis
Endpoint: Treatment success as measured by the Psoriasis Severity Index (PSI) and Plaque Response Assessment scale at day 29 and safety; daily changes in PSI, Plaque Response scale and Pruritus Self-Assessment scores
Status: Phase IIc data
Milestone: NA

Top-line data from the single-blind, U.S. Phase IIc PH-10-PS-23 trial in 99 patients with mild to moderate plaque psoriasis of the trunk and/or extremities showing that 23-29% of patients receiving once-daily topical 0.002%, 0.005% or 0.01% PH-10 achieved complete or near complete resolution of all PSI component symptoms — erythema, induration and desquamation — vs. 0% for vehicle control at 28 days. Provectus also said that the 0.002% and 0.005% formulations of PH-10 showed the maximum improvements in Plaque Response Assessment, with low-dose PH-10 achieving significant improvements on the endpoint vs. vehicle control at 2 weeks (p<0.001). Additionally, 38% of patients receiving low-dose PH-10 reported no itching after 28 days vs. 14% for vehicle control. PH-10 was generally well tolerated with only transient mild to occasionally moderate adverse events limited to the application site reported. Provectus did not disclose next steps.